Search global stocks & ETFs...Ctrl K
Learn Mode
ABBV
Stock Profile
07-31
Recommended Metric
Score Card
Explore Scores Tab
3.74
Good
Valuation Score
Key Score
4.00
Good
Management
4.00
Good
Growth
3.00
Average
Profitability
2.00
Bad
Fin. Health
2.00
Bad
Dividends
1.00
Very Bad
Analyst
4.00
Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$251.06
Baseline
High
$344.40
▲
37.18%
Avg
$257.55
▲
2.58%
Low
$189.76
▼
-24.42%
Analyst Ratings based on 40 Analysts
Strong Buy
923%
Buy
2255%
Hold
923%
Sell
000%
Strong Sell
000%
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).Read More